论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者体表面积(BSA)与口服吉非替尼疗效之间的关系。方法选取2010年1月至2016年9月间河南省内乡县人民医院收治的115例采用吉非替尼单药治疗的EGFR突变的NSCLC患者,使用Cox吉非替尼疗效与体表面积的关系。结果相比于BSA较高(≥1.5m~2)者,吉非替尼对BSA较低(<1.5m~2)患者的疗效更好。两者的总存活时间(OS)无显著差别,较低和较高BSA患者的无进展生存时间(PFS)分别是8.5个月和4.2个月,差异有统计学意义(P<0.05)。BSA对PFS具有显著影响,差异有统计学意义(P<0.05)。结论使用吉非替尼单药治疗的EGFR突变NSCLC患者的BSA越高PFS越低。
Objective To investigate the relationship between the body surface area (BSA) of patients with epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) and the efficacy of gefitinib oral administration. Methods A total of 115 NSCLC patients with EGFR mutations treated with gefitinib monotherapy were enrolled in Neixiang County People’s Hospital of Henan Province from January 2010 to September 2016. The relationship between the efficacy and the body surface area of gefitinib using Cox . Results Compared with high BSA (≥1.5m ~ 2), gefitinib was more effective in patients with lower BSA (<1.5m ~ 2). There was no significant difference between the two groups in the overall survival time (OS). The progression-free survival time (PFS) in patients with low and high BSA was 8.5 months and 4.2 months, respectively, with statistical significance (P <0.05). BSA had a significant effect on PFS, the difference was statistically significant (P <0.05). Conclusions The higher the BSA in patients with EGFR mutation NSCLC treated with gefitinib monotherapy, the lower the PFS.